Autoimmune diseases involve self-tissue destruction by T-cells and antibodies due to lack of self-tolerance. The incidence of autoimmune disease is increasing. Autoimmune diseases can affect almost any part of the body. Antibody therapy is used in numerous diseases including rheumatoid arthritis, multiple sclerosis, lupus, myasthenia gravis and skin blistering diseases.
ARGX-113 is a first-in-class antibody fragment designed for the management of acute autoimmune crisis, which is defined as the sudden and severe onset of symptoms between periods of remission. ARGX-113 has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, systemic lupus erythematosus, myasthenia gravis and skin blistering diseases.
ARGX-110 is a first-in-class SIMPLE Antibody™ which potently blocks CD70 activity. There is a significant unmet need in patients with severe autoimmune diseases who are refractory to current therapies where treatment side-effects remain high (source: Walsh, 2012). Specifically, depleting the small subset of CD70 positive B- and T-cells with minimal impact on the overall B- and T-cell compartments constitutes a rationalized therapeutic goal, potentially associated with a safety advantage.